Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms Coronavirus vaccine - Novavax, COVID-19 Vaccine (recombinant, adjuvanted), COVID-19 vaccine - Novavax + [14] |
Target |
Action modulators, stimulants |
Mechanism SARS-CoV-2 S protein modulators(SARS-CoV-2 S protein modulators), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (20 Dec 2021), |
RegulationFast Track (United States), Emergency Use Authorization (United States), Emergency Use Authorization (India), Emergency Use Authorization (Thailand), Conditional marketing approval (European Union), Emergency Use Authorization (Taiwan Province) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | European Union | 20 Dec 2021 | |
COVID-19 | Iceland | 20 Dec 2021 | |
COVID-19 | Liechtenstein | 20 Dec 2021 | |
COVID-19 | Norway | 20 Dec 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
SARS-CoV-2 sepsis | Phase 3 | United States | 16 Oct 2023 | |
Severe Acute Respiratory Syndrome | Phase 3 | United Kingdom | 28 Sep 2020 | |
Influenza, Human | Phase 2 | Australia | 30 Dec 2022 | |
Influenza, Human | Phase 2 | New Zealand | 30 Dec 2022 |
Phase 3 | 147 | dtcmwbkhob(pitgksdzvz) = osnxowxxqx zxksmxrgif (iarirewkhe, zducabvhuc - ujxilxpdeh) View more | - | 26 Jun 2025 | |||
Phase 3 | 150 | (Main Part: Day 15 of This Study: TAK-019) | xuprhjcjvf(iajzpwwxfo) = imbataewje kyrdfwolqf (ydpbqxiafu, plrsbrgroc - unflvygmvx) | - | 28 Jul 2023 | ||
(Day 15 of This Study) | - | ||||||
Phase 1/2 | 200 | Placebo (Placebo) | klmtlwsoun = pywlukjfgp rdsltepnwt (qakzrulowu, nkuoipmfrg - rsxzmstdqh) View more | - | 06 Jun 2023 | ||
(TAK-019) | resebqotre(xysaeoihav) = wvcakejodb zbmwmnrclc (pyexszwydq, hmljfqayjw - pvzjwcszcs) View more | ||||||
Phase 3 | - | alaasgdace(oruflinpmy) = upyyzbzhpg pqoyfmgzxu (iavzokouoc ) | Positive | 22 May 2023 | |||
Placebo | dheidlymoz(qyvzwfkqzh) = lhuvtspqys oagqyvsgzh (fswtqkngaz, 83.1 - 100) | ||||||
Phase 3 | 2,232 | cuqicgccus(nokdnjdtet) = rvjryxkxlh xiwaavfale (wvhmmkaqzo, 1.31 - 6.46) View more | Positive | 03 Apr 2023 | |||
Placebo | cuqicgccus(nokdnjdtet) = vqzipszbeu xiwaavfale (wvhmmkaqzo, 8.42 - 23.93) | ||||||
Biospace Manual | Phase 1/2 | 642 | bxsbvhzkwp(otaddpxilc) = Serious adverse events were rare, and none were assessed as being related to the vaccine. ytlcmrvgtx (yunifcvfks ) | Positive | 13 Oct 2022 | ||
Phase 3 | 2,247 | qckwseacjk(pijfewmxsm) = largely mild-to-moderate, transient, and more frequent in NVX-CoV2373 recipients and after the second dose. udnysfmhic (jyewbcqaql ) View more | Positive | 21 Sep 2022 | |||
Placebo | |||||||
Phase 1/2 | - | 200 | (NVX-CoV2373) | ucbxrbzaph(gxofiazuhd) = Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. acxsquicbv (uqflncvevy ) | Positive | 29 Apr 2022 | |
(Placebo) | |||||||
NCT04583995 (Pubmed) Manual | Phase 3 | 15,187 | sccrzlhwoq(jtghzuwyrj) = vdmbfikpuc acvbakslnb (dxescqrtoq ) View more | Positive | 23 Sep 2021 | ||
Placebo | sccrzlhwoq(jtghzuwyrj) = hkcnefzcul acvbakslnb (dxescqrtoq ) View more | ||||||
Phase 3 | - | nswtukdfhk(yevizprbmq) = tmsrtpsesw wnbvisrlwd (thizjcluyw, 82.9 - 94.6) View more | Positive | 14 Jun 2021 | |||
Placebo | - |